Anabela Cardoso

TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.

TL;DR: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties as discussed by the authors, which has been shown to reduce mortality in hospitalised adults with COVID-19.

TL;DR: In a case series of patients with bilateral COVID‐19 pneumonia, baricitinib treatment was associated with clinical and radiologic recovery, a rapid decline in SARS‐CoV‐2 viral load, inflammatory markers, and IL‐6 levels, and these data support further evaluation of the anti‐cytokine and anti‐viral activity of baricit inib and support its assessment in randomized trials in hospitalized CO VID‐19 patients.

TL;DR: It is demonstrated that intervention with baricitinib attenuates these circulating biomarkers associated with the cytokine storm and provides insights into mechanisms of SARS-CoV-2 pathogenesis and the host response.

TL;DR: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA).